Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Cytek Biosciences Temettü

Temettü kriter kontrolleri 0/6

Cytek Biosciences şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	0.3%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$0.13
Temettü verim tahmini	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Shares Not Telling The Full Story

Sep 13

An Intrinsic Calculation For Cytek Biosciences, Inc. (NASDAQ:CTKB) Suggests It's 49% Undervalued

Aug 09

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: CTKB şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: CTKB şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Cytek Biosciences Piyasaya Karşı Temettü Getirisi

CTKB temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (CTKB)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.4%
Sektör Ortalaması (Life Sciences)	0.3%
Analist tahmini (CTKB) (3 yıla kadar)	0%

Önemli Temettü: CTKB şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CTKB şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: CTKB şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: CTKB herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Cytek Biosciences Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Shares Not Telling The Full Story

Cytek Biosciences, Inc. Announces Resignation of Paul Christopher Williams as Chief Operating Officer, Effective September 27, 2024

Price target decreased by 8.4% to US$8.70

Consensus EPS estimates fall by 90%

Consensus EPS estimates fall by 52%

An Intrinsic Calculation For Cytek Biosciences, Inc. (NASDAQ:CTKB) Suggests It's 49% Undervalued

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Cytek Biosciences, Inc. Narrows Earnings Guidance for the Year 2024

Cytek Biosciences, Inc. Automates Panel Design with New Intelligent Algorithm

Consensus EPS estimates fall by 15%

Is Cytek Biosciences (NASDAQ:CTKB) Using Debt Sensibly?

Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces an Equity Buyback for $50 million worth of its shares.

Potential Upside For Cytek Biosciences, Inc. (NASDAQ:CTKB) Not Without Risk

Cytek Biosciences, Inc. Reaffirms Earnings Guidance for the Year Ending December 31, 2024

Cytek Biosciences, Inc. to Report Q1, 2024 Results on May 08, 2024

Cytek Biosciences, Inc., Annual General Meeting, Jun 05, 2024

Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader

Cytek Biosciences, Inc. Announces CFO Changes

Cytek Biosciences, Inc. announced delayed annual 10-K filing

Cytek Biosciences, Inc. Provides Earnings Guidance for the Year Ended December 31, 2024

Full year 2023 earnings released

Cytek Biosciences, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2023

Cytek Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry

Cytek Biosciences, Inc. announced delayed 10-Q filing

Cytek Biosciences, Inc. announced delayed 10-Q filing

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2023

CTO & Director notifies of intention to sell stock

Cytek Biosciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Price target decreased by 14% to US$12.25

President notifies of intention to sell stock

Cytek Biosciences Appoints Dr. Philippe Busque Senior Vice President of Global Sales & Services

CTO & Director notifies of intention to sell stock

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cytek Biosciences, Inc. Provides Revenue Guidance for the Full Year 2023

Cytek Biosciences, Inc. to Report Q2, 2023 Results on Aug 08, 2023

CTO & Director notifies of intention to sell stock

President notifies of intention to sell stock

Cytek Biosciences, Inc. (NasdaqGS:CTKB) announces an Equity Buyback for $50 million worth of its shares.

President notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Cytek Biosciences, Inc. Revises Earnings Guidance for the Year 2023

CTO & Director notifies of intention to sell stock

Consensus EPS estimates increase by 22%

Cytek Biosciences' (NASDAQ:CTKB) Solid Profits Have Weak Fundamentals

Price target decreased by 9.1% to US$15.00

Full year 2022 earnings: EPS and revenues miss analyst expectations

Cytek Biosciences, Inc. (NasdaqGS:CTKB) entered into an agreement to acquire Flow Cytometry & Imaging (FCI) business unit of Luminex Corporation for $46.5 million.

President notifies of intention to sell stock

Cytek Biosciences, Inc. to Report Q4, 2022 Results on Feb 28, 2023

CTO & Director notifies of intention to sell stock

President notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

CTO & Director notifies of intention to sell stock

Lead Independent Director exercised options and sold US$229k worth of stock

Cytek Biosciences, Inc. Introduces Cytek Cloud

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2022

Cytek Biosciences, Inc. Names Chris Williams Chief Operating Officer

Cytek Biosciences, Inc. to Report Q3, 2022 Results on Nov 09, 2022

President notifies of intention to sell stock

CTO & Director notifies of intention to sell stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Cytek Biosciences, Inc. Provides Earnings Guidance for the Full Year 2022

Chief Financial Officer notifies of intention to sell stock

Cytek Biosciences Vs. 10x Genomics: 2 Opposing Cell Visualization Investments

Cytek Biosciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Cytek Biosciences, Inc.(NasdaqGS:CTKB) dropped from Russell 2500 Value Index

Cytek Biosciences, Inc. Reaffirms Earning Guidance for 2022

Cytek Biosciences, Inc. Elects Deborah Neff, Don Hardison as Class I Director

CTO & Director notifies of intention to sell stock

President notifies of intention to sell stock

Cytek Biosciences, Inc. Provides Revenue Guidance for the Full Year 2022

Cytek Biosciences, Inc., Annual General Meeting, Jun 01, 2022